Clinical trials
Completed Phase 3 Cardiovascular Diseases trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
230 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 3 |
| 2001 | 4 |
| 2002 | 3 |
| 2003 | 8 |
| 2004 | 10 |
| 2005 | 7 |
| 2006 | 5 |
| 2007 | 7 |
| 2008 | 13 |
| 2009 | 9 |
| 2010 | 11 |
| 2011 | 10 |
| 2012 | 6 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 230 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | 65 |
| Takeda | 11 |
| University of Washington | 6 |
| GlaxoSmithKline | 5 |
| AstraZeneca | 4 |
| Carelon Research | 4 |
| Eli Lilly and Company | 4 |
| Novartis Pharmaceuticals | 4 |
| University of California, San Francisco | 4 |
| Brigham and Women's Hospital | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cardiovascular Diseases | 230 |
| Heart Diseases | 112 |
| Coronary Disease | 66 |
| Myocardial Ischemia | 55 |
| Hypertension | 49 |
| Myocardial Infarction | 42 |
| Vascular Diseases | 31 |
| Diabetes Mellitus | 18 |
| Heart Failure | 17 |
| Obesity | 14 |
Trials
Showing 1 to 25 of 230. Each trial links to its page on Pharma Observatory.
130 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.